Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Completed · Phase 1

Conditions studied: Lymphoma

In brief

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether giving bortezomib together with combination chemotherapy is more effective with or without rituximab in treating AIDS-related non-Hodgkin lymphoma. PURPOSE: This clinical trial is studying giving bortezomib together with dexamethasone, ifosfamide, carboplatin, and etoposide to see how well it works with or without rituximab in treating patients with relapsed or refractory AIDS-related non-Hodgkin lymphoma.

Key facts

Study ID

NCT00598169

Run by

AIDS Malignancy Consortium

People needed

23

Starts

2007-11-01

Expected to finish

2014-11-01

Last updated by the study team

2020-08-10

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100%
• Life expectancy > 2 months
• ANC ≥ 1,000/mm³* (growth factor support allowed)
• Hemoglobin ≥ 8.0 g/dL* (growth factor support allowed)
• Platelet count ≥ 100,000/mm³
• Total bilirubin ≤ 1.5 mg/dL
• AST/ALT ≤ 2.5 times institutional upper limit of normal (ULN)
• Serum creatinine ≤ ULN
• Creatinine clearance ≥ 50 mL/min
• Negative pregnancy test
• Not pregnant or nursing
• Fertile patients must use effective contraception NOTE: *Patients with lymphomatous involvement of the bone unable to meet hematologic criteria are allowed

You may not qualify if…

• Peripheral neuropathy ≥ grade 2
• Uncontrolled intercurrent illness including, but not limited to, any of the following:
• Ongoing or active infection
• Opportunistic infections controlled by antimicrobial or suppressive therapy allowed, unless the investigator judges the infection likely to become life-threatening in the setting of multi-agent chemotherapy
• Symptomatic congestive heart failure
• Unstable angina pectoris
• NYHA class III or IV heat failure
• Myocardial infarction within the past 6 months
• Uncontrolled angina
• Severe uncontrolled ventricular or other cardiac arrhythmias
• Acute ischemia or active conduction system abnormalities by ECG
• Serious psychiatric or medical illness, that would interfere with study compliance
• Social situations that would interfere with study compliance
• Acute active HIV-associated opportunistic infection requiring antibiotic treatment
• Mycobacterium avium or candidiasis allowed unless concurrent therapy with moderate-to-strong CYP3A4 inducers or inhibitors is required
• Chronic myelosuppressive agent therapy allowed provided hematologic criteria are met
• Hypersensitivity to compounds of similar chemical or biological composition to bortezomib, boron, mannitol, ifosfamide, carboplatin, or etoposide
• Concurrent malignancy except carcinoma in situ of the cervix, in situ anal cancer, nonmetastatic nonmelanoma skin cancer, or Kaposi's sarcoma not requiring systemic chemotherapy
• Active hepatitis B infection (hepatitis B surface antigen-positive), unless 1 of the following criteria are met:
• Able to start dual anti-hepatitis B adefovir and telbivudine therapy prior to study
• Receiving dual anti-hepatitis B therapy for at least 12 weeks prior to study with either agent active against HIV (i.e., entecavir, tenofovir, lamivudine, or emtricitabine)
• Concurrent grapefruit juice/fruit or green tea
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Recovered from prior adverse effects due to agents administered more than 3 weeks earlier

Where it is running

• Rebecca and John Moores UCSD Cancer Center — La Jolla, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• UCLA Clinical AIDS Research and Education (CARE) Center — Los Angeles, California, United States
• University of California at Davis Center for Aids Research and Education Services — Sacramento, California, United States
• University of Miami Sylvester Comprehensive Cancer Center - Miami — Miami, Florida, United States
• Emory Winship Cancer Institute — Atlanta, Georgia, United States
• Cancer Research Center of Hawaii — Honolulu, Hawaii, United States
• Northwestern Cancer Center — Chicago, Illinois, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Montefiore Medical Center — The Bronx, New York, United States
• Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
• Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia — Philadelphia, Pennsylvania, United States
• Thomas Street Health Center — Houston, Texas, United States
• Baylor College of Medicine — Houston, Texas, United States
• Virginia Mason Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.